ResultsCNBC-TV18
IKS Health expects business to outpace industry growth from FY29
Positive+13Company event
GreyOak summary
IKS Health anticipates its combined business will grow faster than the industry starting from FY29 following the integration of TruBridge. While TruBridge faces muted growth in the current year due to consolidation, the legacy business continues to outperform the 12% market growth. The company aims to achieve an EBITDA of ₹3,000 crore by FY30.
What it affects
- Inventurus Knowledge SolutionsIKSPositive +13
Expects combined business to outpace industry growthRolling sentiment Positive +15
Source
Read the original at CNBC-TV18More Inventurus Knowledge Solutions news
- Jhunjhunwala portfolio worth Rs 48,000 cr includes Titan, IKSBusiness Today · Stock view ·